Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer
Xin-yuan Yu, Yu-qin Zhu, Xin Liu, Rong Tian, Jun-jie Chen, Guo-qing Liu, Dong-yu Yang, Xue-ping Zhang, Bao Li, Hong-jun Zhao, Xiao Li · 2023
Read Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer by Xin-yuan Yu, Yu-qin Zhu, Xin Liu, Rong Tian, Jun-jie Chen, Guo-qing Liu, Dong-yu Yang, Xue-ping Zhang, Bao Li, Hong-jun Zhao, Xiao Li (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10752594.txt.
Description
A rare prostate cancer that acts like a nerve cell tumour has few good cures, since it barely answers the standard drug and ray paths. Xin-yuan Yu and ten co-authors report a case in 2023 in which a targeted radioactive drug was tried. The patient was a man in his eighties whose blood marker for prostate growth had risen.
The drug pairs a guide that seeks nerve-type cells with a radioactive payload that kills at close range. It is known from work on like tumours in the gut. Prostate cases of this type are scarce, and the research base for their care is thin. The report walks through the man's course and the drug's effect. One case cannot set a standard, but it can point trials toward a fresh path.
Catalog record
| CREATOR | Xin-yuan Yu, Yu-qin Zhu, Xin Liu, Rong Tian, Jun-jie Chen, Guo-qing Liu, Dong-yu Yang, Xue-ping Zhang, Bao Li, Hong-jun Zhao, Xiao Li |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |